Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study — Stella

Recruiting

Back to Osteoporosis trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

Department of Medicine, Tuen Mun Hospital, Hong Kong

Key details

Phase

Post-approval study

Sponsor

Tuen Mun Hospital

Enrollment target

~63 participants

Started

August 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov